Get the Stockscreener App
14.63
2.02%
0.29
After Hours:
14.31
-0.32
-2.19%
Eyepoint Inc stock is traded at $14.63, with a volume of 587.76K.
It is up +2.02% in the last 24 hours and up +10.83% over the past month.
EyePoint Inc focuses is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained-release product candidate for retinal diseases, with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.
See More
Previous Close:
$14.34
Open:
$14.34
24h Volume:
587.76K
Relative Volume:
0.45
Market Cap:
$1.22B
Revenue:
$31.37M
Net Income/Loss:
$-231.96M
P/E Ratio:
-4.6251
EPS:
-3.1632
Net Cash Flow:
$-243.39M
1W Performance:
+3.25%
1M Performance:
+10.83%
6M Performance:
+24.72%
1Y Performance:
+158.02%
1-Day Range:
$14.15
$14.68
1-Week Range:
$13.90
$14.87
52-Week Range:
$5.30
$19.11
Eyepoint Inc Stock (EYPT) Company Profile
Name
Eyepoint Inc
Sector
Industry
Phone
617-926-5000
Address
480 PLEASANT STREET, WATERTOWN, MA
Compare EYPT vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EYPT
Eyepoint Inc
|
14.63 | 1.20B | 31.37M | -231.96M | -243.39M | -3.1632 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Eyepoint Inc Stock (EYPT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-17-25 | Initiated | RBC Capital Mkts | Outperform |
| Jan-07-25 | Initiated | Citigroup | Buy |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Aug-28-24 | Initiated | Jefferies | Buy |
| Jan-22-24 | Initiated | JP Morgan | Overweight |
| Nov-02-23 | Initiated | Mizuho | Buy |
| Apr-21-23 | Initiated | Robert W. Baird | Outperform |
| Jul-07-22 | Initiated | Chardan Capital Markets | Buy |
| Mar-01-21 | Initiated | Cowen | Outperform |
| Jan-28-21 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-06-20 | Downgrade | B. Riley FBR | Buy → Neutral |
| Nov-04-19 | Resumed | Laidlaw | Buy |
| Sep-12-19 | Initiated | Guggenheim | Buy |
View All
Eyepoint Inc Stock (EYPT) Latest News
EyePoint Highlights DURAVYU Phase 3 Progress and Cash Runway - TipRanks
EyePoint posts April 2026 investor presentation; DURAVYU Phase 3 updates, cash runway into Q4 2027 - TradingView — Track All Markets
DURAVYU Phase 3 plans and cash runway outlined by EyePoint (EYPT) - Stock Titan
EyePoint Inc at TD Cowen Healthcare Conference Transcript - GuruFocus
Avoiding Lag: Real-Time Signals in (EYPT) Movement - Stock Traders Daily
Recap Report: What is the long term forecast for EyePoint Pharmaceuticals Inc stockQuarterly Trade Report & Free Community Consensus Stock Picks - baoquankhu1.vn
Stocks to watch: EyePoint sees relative strength rating rise to 92 - MSN
Aug Reactions: What are analysts price targets for EyePoint Pharmaceuticals IncPrice Action & Fast Gain Swing Trade Alerts - baoquankhu1.vn
Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat
Eyepoint Pharmaceuticals (NASDAQ:EYPT) Stock Price Down 3.7%Time to Sell? - marketbeat.com
Aberdeen Group plc Has $29.34 Million Position in Eyepoint Pharmaceuticals, Inc. $EYPT - MarketBeat
EyePoint Inc at RBC Capital Markets Ophthalmology Conference (Virtual) Transcript - GuruFocus
Chardan raises EyePoint stock price target to $29 on cash position - Investing.com
EyePoint, Inc. (EYPT) stock price, news, quote and history - Yahoo Finance UK
Parkman Healthcare Partners LLC's EyePoint Inc(EYPT) Holding History - GuruFocus
Earnings call transcript: Eyepoint Pharmaceuticals Q4 2025 reveals revenue drop - Investing.com
Q3 2025 EyePoint Pharmaceuticals Inc Earnings Call Transcript - GuruFocus
STU:PV3B PB Ratio: 3.51 — 21% Below Median - GuruFocus
EYPT PE Ratio & Valuation, Is EYPT Overvalued - Intellectia AI
EyePoint Inc (EYPT) Stock Price Quote Today & Current Price Chart - capital.com
EyePoint Inc : Jefferies Assumes Coverage Wit - Moomoo
Discipline and Rules-Based Execution in EYPT Response - Stock Traders Daily
Stock List: Research Stocks from Around the World - gurufocus.com
Tech Rally: What is the PEG ratio of EyePoint Pharmaceuticals Inc2026 Outlook & Precise Swing Trade Entry Alerts - baoquankhu1.vn
[SCHEDULE 13G/A] EyePoint, Inc. Amended Passive Investment Disclosure - Stock Titan
EyePoint Pharmaceuticals at RBC Conference: Strategic Progress in Ophthalmology By Investing.com - ca.investing.com
EyePoint Pharmaceuticals Teases August Phase 3 Wet AMD Data for DURAVYU at RBC Ophthalmology Conference - Yahoo Finance
EYPT: DURAVYU phase III trials show strong progress, safety, and reduced treatment burden, with key data due soon - TradingView
EyePoint (EYPT) surges 15.2%: Is this an indication of further gains? - MSN
[Form 4] EyePoint, Inc. Insider Trading Activity - Stock Titan
EyePoint (EYPT) price target increased by 10.87% to 36.80 - MSN
EyePoint lawsuit accuses Ocular of 'malicious' defamation campaign in retina drug race - Fierce Pharma
EyePoint sues rival Ocular Therapeutix, alleging false claims about eye drug - Reuters
EyePoint sues Ocular over claims related to lead asset - MSN
EyePoint (EYPT) Sues Ocular Therapeutix (OCUL) Over False Claims - GuruFocus
EyePoint files a lawsuit against Ocular (EYPT:NASDAQ) - Seeking Alpha
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Q4 2025 earnings call transcript - MSN
EyePoint, Inc. Files Complaint Against Ocular Therapeutix—Key Details from Latest 8-K SEC Filing - Minichart
How The EyePoint (EYPT) Story Is Shifting With Phase 3 DME And Duravyu In Focus - Yahoo Finance
Eyepoint files complaint against Ocular Therapeutix in Middlesex County Superior Court - marketscreener.com
On March 20, 2026, EyePoint has officially filed a lawsuit against biotechnology company Ocular Therapeutix in the Superior Court of Middlesex County, Massachusetts, USA. - Bitget
EyePoint Sues Ocular Therapeutix Over Alleged Defamation - TipRanks
A Look At EyePoint Pharmaceuticals (EYPT) Valuation Following Recent Mixed Share Price Performance - Sahm
Behavioral Patterns of EYPT and Institutional Flows - Stock Traders Daily
Eyepoint Pharmaceuticals pursues new therapies as anti-VEGF treatments fall short for DME patients - Traders Union
EyePoint Pharmaceuticals Q4 2025 earnings preview - msn.com
Risk Hedge: What is the long term forecast for EyePoint Pharmaceuticals Inc stock2026 Geopolitical Influence & Safe Entry Point Identification - baoquankhu1.vn
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - 富途牛牛
EyePoint (EYPT) Is Down 14.2% After Weak Q4 Results And DURAVYU OptimismWhat's Changed - simplywall.st
Eyepoint (EYPT) CEO Duker buys $19,723 in company stock By Investing.com - Investing.com Australia
This Biotech Stock Up 700% Is Still a Top Holding Despite a $9.3 Million Sale Last Quarter - The Motley Fool
Eyepoint Inc Stock (EYPT) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.69%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):